Proteomic analysis at the bedside: early detection of cancer.
Proteomic technologies promise to accelerate rapidly a new era in molecular medicine, especially in the detection and discovery of disease-related biomarkers. These technologies have no bigger impact than in the field of human cancer research. Beyond lifestyle-associated prevention strategies, early detection of cancer has the most profound impact on the ultimate course of the disease: the earlier the cancer is detected, the better the prognosis. Today, new proteomic technologies are being used to discover new diagnostic and prognostic biomarkers for the early detection and treatment of cancer that will have important implications at the bedside.
Petricoin
Emanuel F
EF
FDA-NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. petricoin@cber.fda.gov
Liotta
Lance A
LA
D015415:Biomarkers; D001709:Biotechnology / Q000379:methods; D005260:Female; D006801:Humans; D007834:Lasers; D008297:Male; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000378:metabolism; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism; D020543:Proteome; D013997:Time Factors
D015415:Biomarkers; D020543:Proteome